T-VEC (talimogen laherparepvec)

Imlygic®

An oncolytic, attenuated herpes simplex virus type 1 that replicates selectively in tumor cells and destroys them locally. The production of human GM-CSF also induces a systemic antitumor immune response.

March 2017

T-VEC is indicated as monotherapy for the treatment of unresectable melanoma with regional or distant metastases (stages IIIB, IIIC, and IVM1a) without bone, brain, lung, or other visceral metastases in adults.

Differential blood count, blood chemistry panel.

Before each administration: differential blood count, blood chemistry panel.

First injection: 10⁶ PFU/ml intratumoral (i.t.), starting with the largest metastasis, then the remaining metastases based on lesion size (maximum 4 ml); subsequent injection 3 weeks later. Subsequent injection(s): 10⁸ PFU/ml i.t., starting with new or the largest metastases (maximum 4 ml); injections every 2 weeks.

T-VEC treatment should be continued for at least 6 months as long as injectable lesions remain.

Possible pseudoprogression during treatment with T-VEC. Contraception using latex condoms. To prevent transmission of Imlygic, women must use contraception during treatment.

See medical literature, guidelines, and study results